HRP20021039B1 - Cyclopentanoindoles, compositions containing such compounds and methods of treatment - Google Patents

Cyclopentanoindoles, compositions containing such compounds and methods of treatment

Info

Publication number
HRP20021039B1
HRP20021039B1 HR20021039A HRP20021039A HRP20021039B1 HR P20021039 B1 HRP20021039 B1 HR P20021039B1 HR 20021039 A HR20021039 A HR 20021039A HR P20021039 A HRP20021039 A HR P20021039A HR P20021039 B1 HRP20021039 B1 HR P20021039B1
Authority
HR
Croatia
Prior art keywords
optionally substituted
halogen
independently selected
ora
heteroaryl
Prior art date
Application number
HR20021039A
Other languages
English (en)
Croatian (hr)
Inventor
Labelle Marc
Sturino Claudio
Roy Bruno
Berthelette Carl
Boyd Michael
Lachance Nicolas
Scheigetz John
Original Assignee
Merck Frosst Canada & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada & Co. filed Critical Merck Frosst Canada & Co.
Publication of HRP20021039A2 publication Critical patent/HRP20021039A2/hr
Publication of HRP20021039B1 publication Critical patent/HRP20021039B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/38—TPC being performed in particular situations
    • H04W52/46—TPC being performed in particular situations in multi hop networks, e.g. wireless relay networks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04B—TRANSMISSION
    • H04B17/00—Monitoring; Testing
    • H04B17/30—Monitoring; Testing of propagation channels
    • H04B17/309—Measuring or estimating channel quality parameters
    • H04B17/318—Received signal strength
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W48/00—Access restriction; Network selection; Access point selection
    • H04W48/02—Access restriction performed under specific conditions
    • H04W48/04—Access restriction performed under specific conditions based on user or terminal location or mobility data, e.g. moving direction, speed
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/06—TPC algorithms
    • H04W52/14—Separate analysis of uplink or downlink
    • H04W52/146—Uplink power control
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/28—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non transmission
    • H04W52/288—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non transmission taking into account the usage mode, e.g. hands-free, data transmission, telephone
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W48/00—Access restriction; Network selection; Access point selection
    • H04W48/20—Selecting an access point
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H04W52/245—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters taking into account received signal strength
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04W—WIRELESS COMMUNICATION NETWORKS
    • H04W52/00—Power management, e.g. TPC [Transmission Power Control], power saving or power classes
    • H04W52/04—TPC
    • H04W52/18—TPC being performed according to specific parameters
    • H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
    • H04W52/247—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters where the output power of a terminal is based on a path parameter sent by another terminal

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Quality & Reliability (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Computer Security & Cryptography (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Steroid Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
HR20021039A 2000-07-25 2002-12-30 Cyclopentanoindoles, compositions containing such compounds and methods of treatment HRP20021039B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22068300P 2000-07-25 2000-07-25
PCT/CA2001/001069 WO2002008186A2 (en) 2000-07-25 2001-07-23 Cyclopentanoindoles, compositions containing such compounds and methods of treatment

Publications (2)

Publication Number Publication Date
HRP20021039A2 HRP20021039A2 (en) 2004-10-31
HRP20021039B1 true HRP20021039B1 (en) 2011-03-31

Family

ID=22824535

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20021039A HRP20021039B1 (en) 2000-07-25 2002-12-30 Cyclopentanoindoles, compositions containing such compounds and methods of treatment

Country Status (34)

Country Link
US (1) US6410583B1 (es)
EP (1) EP1305286B1 (es)
JP (1) JP4119745B2 (es)
KR (1) KR100746814B1 (es)
CN (1) CN1214007C (es)
AT (1) ATE284388T1 (es)
AU (2) AU2001277430B2 (es)
BG (1) BG66084B1 (es)
BR (1) BR0112756A (es)
CA (1) CA2416867C (es)
CZ (1) CZ2003236A3 (es)
DE (1) DE60107687T2 (es)
DK (1) DK1305286T3 (es)
DZ (1) DZ3402A1 (es)
EA (1) EA006765B1 (es)
EC (1) ECSP034428A (es)
EE (1) EE05287B1 (es)
ES (1) ES2231526T3 (es)
GE (1) GEP20053595B (es)
HK (1) HK1058934A1 (es)
HR (1) HRP20021039B1 (es)
HU (1) HUP0301745A3 (es)
IL (2) IL153406A0 (es)
IS (1) IS2170B (es)
MX (1) MXPA03000710A (es)
NO (1) NO325011B1 (es)
NZ (1) NZ523106A (es)
PL (1) PL207342B1 (es)
PT (1) PT1305286E (es)
RS (1) RS50491B (es)
SK (1) SK287507B6 (es)
UA (1) UA73787C2 (es)
WO (1) WO2002008186A2 (es)
ZA (1) ZA200300554B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217725B2 (en) * 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
US7273883B2 (en) * 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
ES2230382T3 (es) * 2000-11-03 2005-05-01 Wyeth Ciclopental(b)(1,4)diazpino(6,7,1-hi)indoles como antagonistas de 5ht2c.
AR031199A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
US7141563B2 (en) 2000-11-03 2006-11-28 Wyeth Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi] indole derivatives
AR031200A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
AR031196A1 (es) 2000-11-03 2003-09-10 Wyeth Corp Procedimiento para la preparacion de ciclopenta (b) (1,4)-diazepino (6,7,1-hi) indoles y derivados
US6777407B2 (en) 2000-11-03 2004-08-17 Wyeth Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
US6916922B2 (en) 2000-11-03 2005-07-12 Wyeth Process for the preparation of 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta [B] [1,4] diazepino- [6,7,1-hi] indole derivatives
AR038136A1 (es) * 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200400818A (en) 2002-05-21 2004-01-16 Wyeth Corp Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
TW200400963A (en) 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
AR041089A1 (es) * 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
US20070054951A1 (en) * 2003-05-20 2007-03-08 Lianhai Li Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
CN1805959A (zh) * 2003-06-12 2006-07-19 麦克弗罗斯特加拿大有限公司 作为dp拮抗剂的环烷吡咯并吡啶
EP1656141B1 (en) * 2003-08-07 2010-04-14 MERCK SHARP & DOHME LTD. Treatment for alzheimer s disease and related conditions
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
EP1768674A1 (en) 2004-07-16 2007-04-04 ProteoSys AG Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
GT200500284A (es) * 2004-10-15 2006-03-27 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006113150A1 (en) * 2005-04-13 2006-10-26 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
US7902177B2 (en) 2005-05-02 2011-03-08 Wandzel Richard A Treatment of congestion using steroids and adrenergics
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
MX354134B (es) 2008-07-23 2018-02-14 Arena Pharm Inc Derivados de acido 1,2,3,4-tetrahidrociclopenta [b] indol-3-il) acetico sustituidos utiles en el tratamiento de enfermedades autoinmune e inflamatorias.
CA2733671C (en) 2008-08-27 2018-01-02 Arena Pharmaceuticals, Inc. Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
WO2010030360A1 (en) 2008-09-11 2010-03-18 Arena Pharmaceuticals, Inc. 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
CA2737618A1 (en) 2008-09-25 2010-04-01 Merck Frosst Canada Ltd. Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
WO2010081823A1 (en) 2009-01-13 2010-07-22 Proteosys Ag Pirenzepine as otoprotective agent
CN102741244A (zh) 2009-10-26 2012-10-17 拜耳作物科学公司 4-[[(6-氯吡啶-3-基)甲基](2,2-二氟乙基)氨基]呋喃-2(5h)-酮的新固体形式
EP4148045A1 (en) 2010-01-27 2023-03-15 Arena Pharmaceuticals, Inc. Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof
SG10201501575VA (en) 2010-03-03 2015-04-29 Arena Pharm Inc Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
JP6770522B2 (ja) * 2015-02-13 2020-10-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
US11279656B2 (en) * 2017-10-27 2022-03-22 Applied Materials, Inc. Nanopowders, nanoceramic materials and methods of making and use thereof
US11555015B2 (en) 2018-09-06 2023-01-17 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN115260173A (zh) * 2021-04-30 2022-11-01 厦门宝太生物科技股份有限公司 环戊烷并吲哚类支链酸衍生物及其制备方法和应用
CN116854622A (zh) * 2023-07-10 2023-10-10 青岛科技大学 一种多取代的2,4-二氢环戊二烯并[b]吲哚类化合物的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
EP0234708A1 (en) * 1986-01-23 1987-09-02 Merck Frosst Canada Inc. Tetrahydrocarbazole 1-alkanoic acids
EP0468785A2 (en) * 1990-07-26 1992-01-29 Merck Frosst Canada Inc. (Quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787444A (fr) 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
GB9101375D0 (en) 1991-01-22 1991-03-06 Erba Carlo Spa N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
AU714312B2 (en) * 1995-06-21 1999-12-23 Shionogi & Co., Ltd. Bicyclic amino derivatives and PGD2 antagonist containing them
CN1105112C (zh) * 1996-12-13 2003-04-09 盐野义制药株式会社 苯并噻吩酰胺类衍生物以及含有它们的pgd2拮抗剂
DE69925270T2 (de) * 1998-06-03 2006-02-23 Shionogi & Co., Ltd. Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
EP0234708A1 (en) * 1986-01-23 1987-09-02 Merck Frosst Canada Inc. Tetrahydrocarbazole 1-alkanoic acids
EP0468785A2 (en) * 1990-07-26 1992-01-29 Merck Frosst Canada Inc. (Quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes

Also Published As

Publication number Publication date
BG107438A (bg) 2003-09-30
CZ2003236A3 (cs) 2003-05-14
NO325011B1 (no) 2008-01-14
EA006765B1 (ru) 2006-04-28
CA2416867A1 (en) 2002-01-31
KR20030024810A (ko) 2003-03-26
NZ523106A (en) 2005-01-28
DK1305286T3 (da) 2005-03-14
JP2004504380A (ja) 2004-02-12
IL153406A0 (en) 2003-07-06
DE60107687T2 (de) 2005-12-01
IL153406A (en) 2008-03-20
BG66084B1 (bg) 2011-03-31
BR0112756A (pt) 2003-06-24
HRP20021039A2 (en) 2004-10-31
SK932003A3 (en) 2003-06-03
PL363168A1 (en) 2004-11-15
GEP20053595B (en) 2005-08-10
CN1443165A (zh) 2003-09-17
EE05287B1 (et) 2010-04-15
IS2170B (is) 2006-11-15
ATE284388T1 (de) 2004-12-15
HUP0301745A3 (en) 2010-03-29
HK1058934A1 (en) 2004-06-11
CN1214007C (zh) 2005-08-10
SK287507B6 (sk) 2010-12-07
EE200300033A (et) 2004-10-15
NO20030374D0 (no) 2003-01-24
DZ3402A1 (fr) 2002-01-31
EP1305286A2 (en) 2003-05-02
ZA200300554B (en) 2004-04-23
HUP0301745A2 (hu) 2003-09-29
AU2001277430B2 (en) 2006-05-25
IS6655A (is) 2002-12-12
PL207342B1 (pl) 2010-12-31
CA2416867C (en) 2008-03-25
EP1305286B1 (en) 2004-12-08
ECSP034428A (es) 2003-03-10
DE60107687D1 (de) 2005-01-13
RS50491B (sr) 2010-03-02
YU97902A (sh) 2006-05-25
KR100746814B1 (ko) 2007-08-06
ES2231526T3 (es) 2005-05-16
UA73787C2 (en) 2005-09-15
US6410583B1 (en) 2002-06-25
PT1305286E (pt) 2005-04-29
EA200300171A1 (ru) 2003-06-26
WO2002008186A3 (en) 2002-03-21
JP4119745B2 (ja) 2008-07-16
AU7743001A (en) 2002-02-05
NO20030374L (no) 2003-01-24
MXPA03000710A (es) 2003-06-04
WO2002008186A2 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
HRP20021039B1 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
DE69501947D1 (de) SUBSTITUIERTE AROMATISCHE VERBINDUNGEN ALS c. AMP PHOSPHODIESTERASE-UND TNF-HEMMER
DE60025938D1 (de) Triphenylalkenderivate und ihre anwendung als selektive modulatoren des östrogenrezeptors
RS50519B (sr) Supstituisani derivati 8'-piri(mi)dinil-dihidrospiro- /cikloalkilamin/-pirimido/1,2-a/pirimidin-6-ona
ME00564A (en) (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists
RS52134B (sr) Modulatori receptora glukokortikoida
CY1106497T1 (el) Νεες αρυλοξυ-αλκυλ-διαλκυλαμινες
IS7118A (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfnæmissjúkdómum
FI915970A0 (fi) Laekemedel, som aer nyttiga vid vaord av cancer och som har antihistaminegenskaper.
HUP9903758A2 (hu) Benzoxazinon dopamin D4 receptor antagonisták és az ezeket tartalmazó gyógyszerkészítmények
HRP20070498T3 (en) Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them
SE7602122L (sv) Nya piperazinyliminorifamyciner och sett att framstella desamma
HUP9900584A2 (hu) Új benzoil-guanidin-származékok, eljárás előállításukra és gyógyszerkészítmények előállításában való felhasználásuk
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
FI942928A (fi) Fenyleenidialkanoaattien aromaattiset esterit ihmisen neutrofiili-elastaasin inhibiittoreina
RS50432B (sr) Novi tetrahidropiridini, postupak njihovog dobijanja i farmaceutski preparati koji ih sadrže
HRP20000878B1 (en) Chemical synthesis of morpholine derivatives
CO4920251A1 (es) Compuestos hexahidro 1 h. -pirrolizina 7 a. -heterociclico- substituidos utiles en el control de la transmision sinaptica quimica
MEP12108A (en) Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them
DK1471059T3 (da) 2,4,6-tris(dineopentyl-4'-aminobenzalmalonat)-s-triazin, fotobeskyttende kosmetiske sammensætninger indeholdende denne forbindelse og anvendelse af den nævnte forbindelse
YU44592A (sh) Derivati 4-aril-3-(heteroarilkarbamido) hinolina
YU47605B (sh) Postupak za dobijanje supstituisanih derivata stirena
DE69311500D1 (de) 2,3-Diphenyl-5-pyrrolyl-furan Derivate, Verfahren und Zwischenprodukte für ihre Herstellung und ihre Verwendung als entzündungshemmende, antiallergische und blutplättchenaggregationshemmende Mittel
ES8105704A1 (es) Procedimiento de preparacion de nuevos eteres oximas, de sussales de adicion acidas y de sus derivados amonicos cuater- narios
EA200401077A1 (ru) 2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20130716

Year of fee payment: 13

PBON Lapse due to non-payment of renewal fee

Effective date: 20140723